Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting <scp>IL</scp>‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years

2 Apr 2024

Abstract excerpt

BACKGROUND: Tralokinumab is a monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of skin inflammation and barrier abnormalities in atopic dermatitis (AD). This study evaluated early and 2-year impacts of IL-13 neutralization on skin and serum biomarkers following tralokinumab treatment in adults with moderate-to-severe AD. METHODS: Skin biopsies and blood samples were evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Dermatology and Skin Diseases
Share to Psoriasis: Treatment and Pathogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38563683
DOI: 10.1111/all.16108

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting <scp>IL</scp>‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 yearsPMID 38563683Read ↗

Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic InnovationSemantic proximity Read ↗

Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitroSemantic proximity Read ↗

The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.Semantic proximity Read ↗

Comprehensive Transcriptomic Analysis of Atopic Dermatitis Patients Documents the Spectrum of Molecular Abnormalities and the Response to TreatmentSemantic proximity Read ↗

IL-24 and S100A2 as Novel Immune Drivers for Therapeutic Targeting and Precision Subtyping in Atopic DermatitisSemantic proximity Read ↗

Immunological Differences in Atopic Dermatitis Across Age Groups: Insights from Single-Cell Multi-OmicsSemantic proximity Read ↗

Deciphering atopic dermatitis heterogeneity: a short review on the translational revolution from endotypes to immunotypes.Semantic proximity Read ↗

Deconstruction of immune-mediated skin diseases defines six inflammatory subtypes.Semantic proximity Read ↗

Untangling the Complexity of Childhood Atopic Dermatitis: Phenotypes and Endotypes.Semantic proximity Read ↗

Multi-modal skin atlas identifies a multicellular immune-stromal community associated with altered cornification and specific T cell expansion in atopic dermatitisSemantic proximity Read ↗

Spontaneously Resolved Atopic Dermatitis Shows Melanocyte and Immune Cell Activation Distinct From Healthy Control SkinSemantic proximity Read ↗

Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.